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ABSTRACT 
 
Activation of the maternal immune system and resultant maternal cytokine 
expression due to prenatal infection has been implicated as a significant contributor to 
the pathology of neuropsychiatric and neurodevelopmental disorders such as 
schizophrenia and Autism Spectrum Disorder (ASD).  Increased maternal interleukin-6 
(IL-6) expression, observed clinically and in animal models of prenatal infection, and 
resultant activation of key signaling pathways, has been shown to be a biological 
indicator of pathology, and a central component of the pathological mechanism.  In 
animal models of prenatal infection and clinically in pregnancy disorders hallmarked by 
immunological irregularities and increased IL-6 expression, inhibition of IL-6 has been 
shown to reduce pathological symptoms both maternally and in the exposed offspring.  
This study aims to demonstrate the ability of IL-6 expression, resulting from prenatal 
infection, to induce neuropathological and behavioral outcomes that mirror clinical 
observations seen in disorders such as ASD.  More importantly, it shows how flavones 
luteolin and diosmin, a subclass of the flavonoid family, through inhibition of IL-6 
mediated activation of Signal Transducer and Activator of Transcription-3 (Stat3) can 
reduce these pathologies both in vitro and in vivo.   
Evidence suggests that flavonoids, a polyphenolic class of naturally occurring 
plant secondary metabolites, are potent anti-inflammatory agents that can attenuate the 
expression of cytokines such as IL-6, possibly through the modulation of tyrosine kinase 
activity.  They have been shown to have significant therapeutic potential in disorders 
hallmarked by increased inflammation or disruptions in immune regulation, such as 
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neurodegenerative disorders and certain cancers.  Members such as diosmin have also 
been shown to be safe during pregnancy, and are currently utilized in the treatment of 
certain vascular disorders associated with pregnancy.   
In vitro work undertaken in this study showed that co-administration of luteolin 
with IL-6 in neural stem cells (NSC) was able to attenuate pathological outcomes 
induced by IL-6 including aberrant proliferation, over expression of astroglial marker, 
glial fibrillary acidic protein (GFAP) and changes in cellular morphology.  In vivo studies 
involving luteolin and diosmin further confirmed the therapeutic efficacy of these 
compounds as similar attenuation of IL-6 mediated maternal and fetal pro-inflammatory 
cytokine expression and abnormal behaviors in prenatally exposed offspring was 
observed.  Mechanistically, these effects were mediated through inhibition of Stat3 
activation although other pathways activated by IL-6 were modulated by flavone co-
treatment.  Flavonoid treatment during periods of prenatal infection may prove to be a 
therapeutic intervention for the resultant pathological outcomes seen in offspring through 
attenuation of the maternal and fetal immune response to infection as well as modulation 
of signaling pathways in the fetal brain. These compounds may prove therapeutically 
efficacious for the application in perinatal conditions hallmarked by increased 
inflammation during pregnancy. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Autism Spectrum Disorder (ASD) 
It is estimated that approximately 13% of children in the U.S. ages 3 to 17 suffer 
from at least one developmental disability that affects their behavior, memory, or 
learning capability (Boulet et al., 2009, Boyle et al., 2011).  The resulting impact on the 
social, economic, educational, and health care delivery systems are significant, as the 
economic cost of neurodevelopmental disorders in the US have been estimated to be 
$81.5 to $167 billion per year (Boyle et al., 1994).  Recently, Autism Spectrum Disorder 
or autism (ASD) has gained significant focus as there has been an unprecedented 
increase in the number of children diagnosed with the disorder, with an average increase 
of 57% between 2002 and 2006 (Autism and Developmental Disabilities Monitoring 
Network Surveillance Year 2006 Principal Investigators; Centers for Disease Control and 
Prevention, 2009).  Although this increased prevalence has been attributed to 
improvements in diagnostic criterion, it has nonetheless underscored the necessity for 
increased research as an exact etiology for the disorder is still unknown.  This increased 
prevalence, coupled with the lack of a definitive etiological factor and therapeutic options 
for patients and their families has fueled the urgency felt by parents, clinicians and 
researchers to find a definitive etiology and therapeutic strategy for this disorder which 
often carries a significant economic and emotional burden with lifetime care cost 
estimated at $3.2 million per individual (Ganz, 2007) 
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The term autism was originally used by Eugen Bleuler to describe a cluster of 
symptoms in schizophrenic individuals that included withdrawal or ‘self-isolation’.  The 
term would later be used by Leo Kanner in 1943 and Hans Asperger in 1944, to describe 
a similar group of symptoms in children.  Today however, the term autism is often used 
synonymously for Autism Spectrum Disorder (ASD) to describe the cluster of symptoms 
manifested in children displaying withdrawn or ‘isolated’ social behaviors (American 
Psychiatric Association, 2000).  The definition has now evolved to describe the group or 
spectrum of behaviors characterized by impairments in reciprocal social interaction and 
verbal and nonverbal communication skills compounded by symptoms of restrictive and 
repetitive behaviors and/or stereotyped patterns of interest that are abnormal in intensity 
or focus (American Psychiatric Association, 2000, Koenig and Scahill, 2001, 
Zwaigenbaum et al., 2005).  Included in this spectrum is ‘classical’ autism, which usually 
involves social isolation, impaired verbal communication and stereotypical and repetitive 
behaviors; Asperger syndrome, often described as a milder form of autism, lacking the 
components of impaired verbal communication skills while retaining the intense 
repetitive behaviors and difficulties in social interaction.  Also in the spectrum is 
pervasive developmental disorder that usually encompasses disorders that cannot 
otherwise be classified (American Psychiatric Association, 2000, Allen et al., 2001, 
Koenig and Scahill, 2001, Zwaigenbaum et al., 2005).  
Despite the advances in diagnostic criterion, the exact etiology of ASD has not 
been identified, and although there have been significant advancements made in the 
identification of key genes that are abnormally expressed within the autistic population a 
single gene candidate has not been found (Andres, 2002, Belmonte and Bourgeron, 
2006, Bernardet and Crusio, 2006, Chen et al., 2006, Campbell et al., 2008, Li et al., 
2008, Tetreault et al., 2009, Virkud et al., 2009, Kim et al., 2011). The genetic variation 
and phenotypic heterogeneity within this population has led researchers to suggest 
3 
 
alternative hypotheses including the collective contributions of multiple genetic 
disruptions as well as the synergistic interaction of environmental factors with genetic 
polymorphisms or instabilities (Hornig et al., 1999, Fatemi et al., 2002, Fatemi et al., 
2005, Campbell et al., 2008, Fatemi et al., 2008b).   
Prenatal infection has been one such ‘environmental factor’ with observations 
from murine studies confirming the potential for prenatal infection, and more importantly 
the resulting activation of the maternal immune system, to induce aberrant neurological 
and behavioral outcomes in offspring reminiscent of the phenotypes observed clinically 
in disorders such as schizophrenia and ASD  (Fatemi et al., 2002, Shi et al., 2003, 
Zuckerman et al., 2003, Fatemi et al., 2005, Smith et al., 2007, Fatemi et al., 2008b, 
Winter et al., 2008, Ibi et al., 2009, Kirsten et al., 2010, Ghiani et al., 2011).  Similarly, 
epidemiological data and clinical cases of prenatal infection have supported the potential 
for this event to precipitate adverse neurological outcomes with an increased incidence 
of preterm births and cerebral palsy, a neurological disorder involving impairments in 
motor and cognitive function, visual and auditory perception observed in prenatally 
exposed infants.  Fetal Inflammatory Response Syndrome (FIRS), a disorder 
characterized by systemic inflammation and uncharacteristically high levels of plasma IL-
6 in the affected newborn as well as increased circulating IL-6 in the placental and 
umbilical cord plasma is also seen in infants exposed prenatally to intra-amniotic 
bacterial infection or viral infection and often results in preterm births, and adverse 
neurological outcomes such as cerebral palsy (Gomez et al., 1998, Chaiworapongsa et 
al., 2002, Gotsch et al., 2007).   
 
1.2 Prenatal infection, Cytokines and Pregnancy  
Although the exact mechanism may not be fully understood, the activation of the 
maternal immune system following prenatal infection, and specifically the increases in 
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pro-inflammatory cytokine expression has been shown to be integral in precipitating the 
adverse neurological and behavioral outcomes observed in prenatally exposed offspring 
(Ashdown et al., 2006, Fortier et al., 2007, Jonakait, 2007, Ghiani et al., 2011).  
Cytokines, small signaling molecules secreted by cells to mediate intercellular 
communication, have long been shown to play a vital role in immune regulation, 
particularly in the progression of inflammatory responses to stimuli including pathogenic 
insults (Bromberg and Wang, 2009, Sweeney, 2011, Liu et al., 2012).  Their role extends 
beyond their pathological activities however as they have been shown to be equally 
important in physiological events particularly the development and function of various 
cellular populations.  In the immune system, cytokines regulate the differentiation and 
mobilization of T-cell populations, an important event in response to pathogenic stimuli 
as well as during pregnancy (Makhseed et al., 2000, Schluns and Lefrancois, 2003, 
Norton et al., 2010, Robertson et al., 2010, Zhu and Paul, 2010, Zwirner and Domaica, 
2010, Morrison et al., 2011, Tower et al., 2011).  It is this regulatory role that may begin 
to explain the implications of maternal immune activation during prenatal infection in 
precipitating adverse perinatal outcomes as disruptions in cytokine expression have 
been observed in adverse perinatal outcomes (Tosun et al., 2010, Vitoratos et al., 2010, 
Hsiao and Patterson, 2011, Wang et al., 2011).    
During pregnancy, cytokines serve as regulators at the maternal-fetal immune 
interface, preventing maternal rejection of the fetus by maintaining the balance between 
immune-suppressive regulatory T cells (T-regs) and cytotoxic T cells (Th1, Th17) 
(Piccinni and Romagnani, 1996, Makhseed et al., 2000, Piccinni et al., 2000, Piccinni, 
2002, Kanellopoulos-Langevin et al., 2003, Aluvihare et al., 2004, Poole and Claman, 
2004, Aluvihare et al., 2005, Petroff, 2005, Piccinni, 2005, 2010, Saito et al., 2010, 
Shima et al., 2010).  Murine models and human clinical studies have confirmed this 
interplay, with observations of changes in cytokine expression and a shift in the 
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differentiation of naïve T cells toward a T-regulatory phenotype during the peri-
implantation period (Zenclussen, 2006b, Zenclussen et al., 2006, Guerin et al., 2009, 
Ernerudh et al., 2011, Leigh R. Guerin, 2011). Additionally, adverse pregnancy 
outcomes such as recurrent miscarriages, preeclampsia, and instances of restricted fetal 
growth have been attributed to placental dysfunction, specifically the inability of the 
placenta to fully maintain an immunological balance as increased cytotoxic T-cells, 
particularly Th17 cells, have been observed in these disorders along with increased 
levels of pro-inflammatory cytokines particularly IL6 (Makhseed et al., 2000, Zenclussen, 
2006b, a, Piccinni, 2007, Lai et al., 2010, Laresgoiti-Servitje et al., 2010, Saito et al., 
2010, Tosun et al., 2010, Jin et al., 2011, Liu et al., 2011a, Liu et al., 2011b, Saini et al., 
2011, Raghupathy et al., 2012).   
 
1.3 Cytokines in neurodevelopment 
The activity of cytokines, both physiologically and pathologically have also been 
extensively described beyond their role in the peripheral immune system as they 
participate in the central nervous system (CNS) as key mediators in neurodegenerative 
disorders and other instances characterized by neuroinflammation and also in normal 
CNS development and function (Ajmone-Cat et al., Burns et al., 1993, Pousset, 1994a, 
Zhao and Schwartz, 1998, Balschun et al., 2004, Bauer et al., 2007, Deverman and 
Patterson, 2009, Jellinger, 2010, Appel et al., 2011, Matousek et al., 2011).  During CNS 
development, cytokines are present and functional in the fetal brain, with receptors 
identified on both neuronal and glial cells (Pousset, 1994b, Rothwell et al., 1996, Dame 
and Juul, 2000).  They exert their regulatory effects propagating permissive or inhibitory 
signals to coordinate the birth and terminal differentiation of neuronal and glial cell 
populations, their migration and positioning in the brain and the formation and 
maintenance of functional synapses (Bauer et al., 2007, Deverman and Patterson, 
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2009).  This regulatory role may explain the ability for pathological expression of 
cytokines such as IL-6, during prenatal infection to produce disruptions in cellular events 
including changes in migratory patterns and synaptic function that may manifest in the 
adverse neurological symptoms observed clinically in disorders such as ASD. 
 
1.4  Prenatal infection and implications for neurodevelopmental disorders:  
Evidence from fetal inflammatory response syndrome (FIRS) 
The idea of an ‘environmental insult’ precipitating neurodevelopmental disorders 
is not a novel hypothesis as several compounds, including toxins and heavy metals, 
have been shown to cause neurological and congenital abnormalities in children 
exposed prenatally (Silbergeld and Patrick, 2005, Wigle et al., 2007, Sutton et al., 2010, 
Schoeters et al., 2011).  The link between prenatal infection and disruptions in fetal 
development is also not a novel idea.  Several researchers have observed correlations 
between maternal infections, pre-term births and neurological disorders such as cerebral 
palsy, ASD and schizophrenia in these prenatally exposed infants (Barak et al., 1999, 
Jacobsson and Hagberg, 2004, Atladottir et al., 2010, Kinney et al., 2010, Monji et al., 
2011).  FIRS is one example of how prenatal infection can lead to adverse pregnancy 
outcomes and compromise fetal development.  FIRS is observed in fetuses and 
newborn infants exposed to infections in utero and is characterized by systemic 
inflammation including abnormally high levels of IL-6 and has been correlated with an 
increased occurrence of neurological disorders such as cerebral palsy.  Although 
described in the context of fetal pathology, FIRS is precipitated by maternal infection, 
specifically, bacterial infections of the amniotic fluid, placenta, uterus or fetal 
membranes, although viral infections can induce similar pathologies (Fahey, 2008).  
Known as intra-amniotic infections, they elicit maternal and fetal immunological 
responses including cytokine release, leukocyte migration and rupture of the fetal 
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membranes.  It is this inflammatory response that is thought to induce maternal and fetal 
pathological outcomes including preterm birth and neurological disruptions (Gomez et 
al., 1998, Romero et al., 2000, Romero et al., 2003, Jacobsson and Hagberg, 2004, 
Gotsch et al., 2007, Fahey, 2008, Fuksman and Mazzitelli, 2009).  Additionally, murine 
models of prenatal infection have also mirrored clinical findings in FIRS including 
observations of increased maternal cytokines such as IL-6 which appear to precipitate 
the adverse behaviors and neuropathologies observed in exposed offspring.  
 
1.5 Prenatal infection and neurodevelopmental disorders– IL-6 as a central 
mechanism and therapeutic target 
Indeed findings from FIRS, murine models of prenatal infection and preeclampsia 
have supported a role maternal and potentially fetal inflammatory response and cytokine 
expression, particularly IL-6, in the adverse perinatal outcomes precipitated by prenatal 
infection including the behavioral abnormalities in exposed offspring (Boksa, 2004, 
Zenclussen, 2006a).  These models have shown that IL-6 is a key component of the 
pathological mechanism, with its inhibition attenuating pathological symptoms (Campbell 
et al., 1993, Smith et al., 2007, Tosun et al., 2010, Covey et al., 2011, Wang et al., 
2011).  Although the exact mechanism by which IL-6 contributes to these pathologies 
may not be fully understood, the physiological role of cytokines and in this instance IL-6, 
during CNS development and in immune regulation may help elucidate how its 
disruption following prenatal infection can lead to pathological outcomes.   
A member of the gp130 family of cytokines, IL-6 and its counterparts propagate 
their regulatory and pathological effects through the activation of a common signaling 
component, Signal Transducers and Activators of Transcription (Stat3) (Heinrich et al., 
1998, Deverman and Patterson, 2009, Islam et al., 2009).  It is this common pathway 
that may allow pathological expression of IL-6 during instances of prenatal infection to 
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disrupt placental function and developmental events mediated by Stat3 activity.  The 
differentiation of cytotoxic T-cell populations for example has been shown to be a Stat3 
dependent highly influenced by IL-6 expression.  T-cells play a critical role during 
pregnancy and clinical studies have suggested that T-cell disturbances may play an 
important role in pregnancy disorders (Kimura and Kishimoto, 2010, Saini et al., 2011).  
Similarly, the differentiation of astroglial cells from neural stem cell populations has also 
been shown to be Stat3 dependent and disruptions in this population have been 
observed in neurological disorders associated with prenatal infection such as ASD 
(Brunello et al., 2000, He et al., 2005, Islam et al., 2009, Bilbo, 2011, Sicca et al., 2011).   
Observations that the inhibition of IL-6 may attenuate pathological symptoms 
arising from prenatal infection have provided a potential mechanism for understanding 
the role of IL-6 in these pathologies as well as a new strategy that can be utilized to 
develop therapeutic alternatives.  In preeclampsia for example, a disorder in pregnancy 
characterized by the sudden onset of hypertension and protein in the urine after the 20th 
week, increased levels of IL6 has been identified as a key indicator of disease pathology 
as well as a therapeutic target with its inhibition attenuating hypertensive symptoms and 
other associated pathologies (Lockwood et al., 2008, Lamarca et al., 2011, Zhou et al., 
2011).  Similarly in murine models of prenatal infection, increased levels of IL-6 have 
been observed following infection and have been shown to play a major role in the 
neuropathologies and abnormal behaviors seen in the exposed offspring while the 
inhibition of IL-6, and Stat3 activity have been shown to counteract these pathologies 
(Smith et al., 2007).  
 
1.6 Therapeutic potential of Flavonoids – ‘Flavones’  
Recently flavonoids, a class of polyphenolic plant metabolites have gained 
significant attention in cancer and inflammation research because of their therapeutic 
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potential, acting as immune modulators in various pathological disorders (Hirano et al., 
2004, Kawai et al., 2007, Seelinger et al., 2008, Geraets et al., 2009).  Grouped on the 
basis of their structural attributes, flavonoids have properties ranging from anti-
inflammatory to anti-carcinogenic attenuating immune reactions in inflammatory cells 
and aberrant proliferation in cancer cells largely through the modulation of tyrosine 
kinase activity.  Luteolin, a member of the flavone class of flavonoids, and found in 
chamomile and celery among other plants, is known to have significant anti-inflammatory 
and anti-tumor potential attenuating cytokine production in immune cell populations, 
while displaying pro-apoptotic properties in tumor cell lines and murine models of cancer 
(Rezai-Zadeh et al., 2008, Seelinger et al., 2008, Kang et al., 2011).  Luteolin, like many 
of the other flavonoids has also been shown to be blood-brain barrier permeable, a 
characteristic that makes it an appealing therapeutic strategy for the neurological 
disorders precipitated by prenatal infection, when coupled with its anti-inflammatory 
potential (Jang et al., 2008).  Diosmin, a semisynthetic flavonoid derivative, has also 
been shown to have similar therapeutic potential being utilized for the treatment of 
vascular disorders.  This research outlines how flavonoids luteolin, and diosmin, can 
inhibit the adverse effects of IL6, including the disruptions in maternal immunity following 
prenatal infection and the neuropathological and behavioral abnormalities observed in 
the exposed offspring, potentially serving as a useful therapeutic intervention during 
instances of prenatal infection and immune dysfunction during pregnancy. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Reagents 
Luteolin (>95% purity by HPLC) was generously donated by Pharma Science 
Nutrients (Ocala, FL, USA).  Diosmin (>90% purity by HPLC) was purchased from Axxor 
(San Diego, CA, USA).  Antibodies against Jak2, phospho-Jak2, Stat3, phospho-Stat3, 
phospho-PI3K, phospho-Akt, Akt, phosphor-ERK1/2 (p44/42), vimentin and nestin were 
obtained from Cell Signaling Technology (Danvers, MA, USA).  Antibodies against 
GFAP, Doublecortin (DCX), and Beta-tubulin were obtained from Abcam (Cambridge, 
MA, USA). Murine recombinant IL-6 (mIL-6 or IL-6) and cytokine ELISA kits were 
purchased from eBioscience (San Diego, CA, USA). BCA protein assay kit was 
purchased from Pierce Biotechnology (Rockford, IL, USA) and Cyquant Cell Proliferation 
assay kit from Invitrogen (Grand Island, NY).   
 
2.2 Cell culture 
2.2.1 Murine derived Primary neural stem cells (NSC) 
Cerebral cortices isolated from C57BL/6 mouse embryos, 14 days in utero were 
obtained from Stem Cell Technologies.  In preparation for culture, neurospheres were 
mechanically dissociated, centrifuged at 90 x g for 5 minutes, and resuspended and 
maintained in 1:1 Dulbecco’s Modified Eagle Medium: Nutrient Mixture F12 (DMEM/F12) 
supplemented with 2% B27 serum free supplement, 5µg/µl fibroblast growth factor (FGF, 
Sigma-Aldrich, St. Louis, MO, USA) and 10µg/ml epidermal growth factor (EGF, Sigma-
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Aldrich, St. Louis, MO, USA).  Prior to treatment, cells were plated in 96 well collagen-
coated culture plates at a density of 2x104 cells per well, 8 well collagen coated, poly-d-
lysine treated culture plates at a density of 2.5 x 105 cells per well, or 6 well collagen-
coated culture plates at a density of 1 x 106.  All cultures were maintained in the 
previously described media formulation prior to treatment unless otherwise indicated and 
incubated at 37°C in 10% CO2 before and during treat ment.  
 
2.2.2 Murine immortalized neuroblastoma cells (N2a) 
N2a (murine neuroblastoma) cells, purchased from the American Type Culture 
Collection (ATCC, Manassas, VA) were maintained in complete DMEM supplemented 
with 10% fetal calf serum.  Cells were plated in 96 well collagen-coated culture plates at 
a density of 2x104 cells per well, or 6 well collagen-coated culture plates at a density of 
1x106 cells per well.  All cultures were maintained in the previously described media 
formulation prior to treatment and incubated at 37°C  in 10% CO2 before and during 
treatment.   
 
2.2.3 Murine derived primary splenocytes 
Spleens isolated from female C57BL/6 mice were dissected and mechanically 
dissociated to obtain a single cell suspension.  Cells were re-suspended and washed in 
complete Roswell Park Memorial Institute 1640 (RPMI 1640) containing 10% serum, 
centrifuged at 400 x g for 5 minutes, then washed in PBS, followed by centrifugation at 
400 x g for 5 minutes. To remove red blood cells, splenocytes were resuspended in ACK 
lysis buffer and incubated per manufacturer’s instructions.  Cells were washed 3 times in 
PBS, resuspended in RPMI 1640 containing 10% serum, and incubated at 37ºC, 5% 
CO2 prior to treatment. 
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2.2.4 Treatments 
For proliferation experiments, after overnight incubation cells incubated in 96 well 
plates were treated with various concentrations of murine recombinant IL-6 (0, 3.125, 
6.25, 12.5, 25, 50ng/mL) or cotreated with 50ng/mL murine recombinant IL-6 and 
various concentrations of luteolin (0, 1.25, 2.5, 5, 10, 20 µM) for 24 hours.  For western 
blot analysis, cells were treated with 50 ng/mL murine recombinant IL-6 for a range of 
time points (0, 15, 30, 45, 60 or 75 minutes) or 50 ng/mL murine recombinant IL-6 in the 
presence of various concentrations of luteolin (0, 1.25, 2.5, 5, 10, 20 µM) for 30 minutes.  
For immunocytochemistry, cells were treated with 50 ng/mL murine recombinant IL-6 in 
the presence or absence of 20uM luteolin.   
For assays performed under differentiated conditions, neural stem cells were 
incubated in neurobasal media supplemented with 2% B27 while neuroblastoma cells 
were incubated in neurobasal media supplemented with 3 mM dibuturyl cAMP.  Reagent 
concentrations and length of treatment maintained.  All experiments were performed in 
triplicate. 
 
2.3 Mice 
2.3.1 Housing and maintenance 
C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, MA) and 
maintained in an animal facility of the University of South Florida (USF).  All animals 
were given ad libitum access to food and water and were maintained on a 12-hour 
light/dark schedule.  All subsequent experiments were performed in compliance with 
protocols approved by the USF Institutional Animal Care and Use Committee.   
 
2.3.2 Treatments 
 Pregnant mice were injected intraperitoneally with IL6 (5ug/mouse), 
13 
 
lipopolysaccharide (LPS) (50ug/kg), or phosphate buffered saline (PBS) as control on 
embryonic day 12.5 (E12.5) and divided equally among three separate groups.  The first 
group was co-injected with Luteolin (20mg/kg), the second group was placed on diosmin 
supplemented diets (10 mg/kg/day, 0.005% in NIH31 chow) and the third group co-
injected with the STAT3 inhibitor S31-201.  A minimum of four pregnant females per 
treatment were utilized for all experiments. 
 
2.4 Lysate and homogenate preparation 
 Cultured cells were lysed in ice-cold lysis buffer (20 mM Tris, pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM sodium pyrophosphate, 1 
mM β-glycerolphosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, 1 mM PMSF) for 5 minutes 
followed by scraping.  Lysates were collected, briefly vortexed and centrifuged at 14,000 
x g for 15 minutes at 4º C.   
Mouse brains and spleens were isolated under sterile conditions on ice and 
placed in ice-cold lysis buffer.  Tissues were sonicated on ice for approximately 3 
minutes, allowed to stand for 15 minutes at 4°C, and then centrifuged at 15,000  x g for 
15 minutes at 4°C.  Total protein content in cell lysates a nd tissue homogenates were 
estimated using the bicinchoninic acid assay (BCA protein assay, Pierce Biotechnology) 
per manufactures instructions and normalized. 
 
2.5 Western Blot Analysis 
Aliquots corresponding to 100ug of total protein were electrophoretically 
separated using 12% SDS gels. Electrophoresed proteins were then transferred to 
nitrocellulose membranes (Bio-Rad, Richmond, CA), washed in Tris buffered saline with 
0.1% Tween-20 (TBS/T), and blocked for one hour at ambient temperature in TBS/T 
containing 5% (w/v) non-fat dry milk.  After blocking, membranes were hybridized 
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overnight at 4°C with various primary antibodies.  Me mbranes were then washed three 
times for five minutes each in TBS/T and incubated for one hour at ambient temperature 
with the appropriate HRP-conjugated secondary antibody (1:1,000, Pierce 
Biotechnology).  Primary antibodies were diluted in TBS/T containing 5% BSA and 
secondary antibodies in TBS containing 5% (w/v) of non-fat dry milk.  Blots were 
developed using the luminol reagent (Pierce Biotechnology).  Densitometric analysis 
was conducted using a FluorS Multiimager with Quantity One™ software (BioRad, 
Hercules, CA). For phospho-Stat3 detection, membranes were probed with a phospho-
Ser727 and phosphor-Tyr705 Stat3 antibody (1:1,000) and stripped with stripping 
solution and then re-probed with antibody that recognizes total Stat3 (1:1,000).  Similarly 
for phospho-Jak2 detection, phosphor-Akt, and phosphor-Erk(1/2) membranes were 
probed with appropriated phosphor antibodies  (1:1,000) and stripped and re-probed for 
corresponding total antibody (1:1,000). 
 
2.6 ELISA Cytokine Analysis 
Mouse brain and spleen homogenates were prepared as described above and 
used at a dilution of 1:10 in cell lysis buffer for these assays.  Tissue-solublized 
cytokines were quantified using commercially available ELISAs that allow for detection of 
IL-1β, IL-6 and TNF-α.  Cytokine detection was carried out according to the 
manufacturer’s instruction.  Data was represented as pg of cytokine/mg total cellular 
protein for each cytokine. 
 
2.7 Proliferation Assay 
 Cells plated in 96 well plates were treated as described in cell culture treatments 
subsection.  Following treatment proliferation was quantified using the Cyquant 
proliferation assay per manufactures instructions. 
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2.8 Tissue Section Preparation 
 Postnatal day 0 mice were anesthetized with in an ice bath.  Brains being utilized 
for immunofluorescence and immunohistochemistry were immediately isolated and 
incubated in paraformaldehyde at 4ºC for 24hrs.  Brains were then sequentially 
transferred to increasing concentrations of sucrose for 72hrs up to a final concentration 
of 30% sucrose.  Brains were then cyrosectioned at 30um and placed in freezing media 
until staining. 
 
2.9 Immunofluoresence Analysis 
Cells cultured in eight well culture slides were treated as described outlined in 
chapter 3.  After treatment, cultured cells were washed, and then fixed with 4% 
paraformaldehyde in phosphate-buffered saline (PBS; 0.1 M, pH 7.4) for 30 min at room 
temperature.  Cells were then washed in PBS three times for five minutes each then 
permeabilized with 0.05% Triton X-100 (Sigma), washed with PBS three times for five 
minutes each, then blocked with 5% horse serum in dilution buffer (0.05% Triton X-100) 
for one hour.  Cells were then incubated overnight at 4ºC with various primary antibodies 
diluted in blocking buffer.  After overnight incubation, cells were washed three times for 
five minutes each in PBS and incubated for 45 minutes at room temperature with the 
appropriate HRP-conjugated secondary antibody.  After incubation, cells were washed 
three times for five minutes in PBS, mounted using vector shield with DAPI, and 
analyzed using confocal microscopy. 
 Brain sections were washed three times for five minutes then blocked in 5% 
horse serum for one hour.  Sections were then washed and incubated in primary 
antibody overnight at 4ºC.  After incubation, sections were washed and incubated in 
secondary antibody, for 45 minutes.  Cells were then washed three times for five 
minutes, mounted onto slides and cover slipped with DAPI mounting media. 
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2.10 Immunohistochemistry 
 Brains being utilized for immunohistochemistry studies were prepared as 
mentioned in immunofluorescence procedure.  After incubation in secondary antibody, 
sections were incubated in VectaStain Elite ABC reagent (Vector Laboratories, 
Burlingame, CA) coupled with diaminobenzidine (DAB) substrate.  Stained sections were 
mounted onto coverslips, air dried, and washed in distilled deionized water two times for 
five minutes.  Sections were then rinsed through three rapid changes of ethanol, cleared 
through three xylene washes and cover slipped with permount.  Sections were visualized 
using bright field Olympus BX-51 Sections microscope. 
 
2.11 Behavioral analysis 
2.11.1 Open Field 
 General locomotor activity of mice was assessed using the open field test.  Mice 
were placed in a 50 x 50cm white Plexiglas box brightly lit by fluorescent room lighting 
and six 60 W incandescent bulbs approximately 1.5 m above the box.  Activity was 
recorded by a ceiling-mounted video camera and analyzed from digital video files either 
by the automated tracking capabilities of Ethovision or counted using the behavior 
tracker (version 1.5, www.behaviortracker.com), a software-based event-recorder.  The 
total distance moved and numbers of entries into the center of the arena (central 17 cm 
square) were determined in a 10 minute session.  General activity levels were evaluated 
by measurements of horizontal activity and vertical activity.  Anxiety was also assessed 
by examining the ratio of center distance traveled to total distance traveled. As the 
natural tendency of the mice is to avoid open areas, animals that show greater tendency 
to explore in the center of the field show a lower tendency for anxiety, or the reverse 
situation can indicate a higher anxiety level.  
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2.11.2 Social Interaction 
To assess social interaction, treatment mice were allowed to interact with a 
stranger mouse and the level of interaction, including sniffing and other investigative 
behaviors was measured.  The testing apparatus consisted of a 60 x 40 cm Plexiglas 
box divided into three chambers.  Mice were be able to move between chambers 
through a small opening (6 x 6 cm) in the dividers.  Plastic cylinders in each of the two 
side chambers contained the probe mice, and numerous 1cm holes in the cylinders 
enabled test and probe mice to contact each other.  Test mice were placed in the center 
chamber, with an overhead camera recording their movements.  Mice were allowed five 
minutes of exploration time in the box, after which an unfamiliar, same-sex probe mouse 
from the same experimental group was placed in one of two restraining cylinders 
(Radyushkin et al., 2009).  The Ethovision software (Noldus, Leesburg, VA) program 
measured time spent in each of the three chambers, and social preference was defined 
as follows: (% time spent in the social chamber) - (% time spent in the opposite 
chamber). 
 
2.12 Statistical analysis 
All data were normally distributed; therefore, in instances of single mean 
comparisons, Levene's test for equality of variances followed by t-test for independent 
samples was used to assess significance.  In instances of multiple mean comparisons, 
analysis of variance (ANOVA) was used, followed by post-hoc comparison using 
Bonferroni's method.  Alpha levels were set at 0.05 for all analyses unless otherwise 
indicated.  The STATistical package for the social sciences release 10.0.5 (SPSS Inc., 
Chicago, IL, USA) was used for all data analysis. 
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CHAPTER 3 
 
LUTEOLIN ATTENUATES IL-6 MEDIATED CHANGES IN NEURAL STEM CELLS VIA 
INHIBITION OF STAT3 ACTIVITY: IMPLICATIONS FOR PRENATAL INFECTION 
 
3.1 Regulation of central nervous system (CNS) development 
3.1.1 Role of gp130 cytokines and Stat3 
It has been established that CNS development is an inherently vulnerable period 
with subtle changes in the immediate cellular environment leading to disruptions in the 
morphology and function of neural populations that can precipitate adverse neurological 
outcomes. This vulnerability has been attributed to the high degree of regulation 
necessary during this period to coordinate the actions of the milieu of morphogenic 
factors, including cytokines.  Cytokines are important in the development of the CNS as 
they play a key role in the fate specification and terminal differentiation of neuronal and 
glial populations, the migration of neurons to the final position in the CNS, the formation 
and maintenance of functional synapses, the sequential manner in which these 
cytokines are expressed and the temporal nature in which these events occur 
(Pekkanen-Mattila et al., 2010).  
During early embryogenesis for example, the emergence of the neuroectoderm 
from embryonic stem cells signals the formation of the CNS and coincides with the 
expression of transcription factors such as sex determining region Y – box1 (Sox1).  
Sox1 is implicated in directing the fate specification and expansion of this multipotent 
cellular population as well as ensuring its maintenance through active proliferation and 
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the inhibition of further differentiation (Suter et al., 2009, Elkouris et al., 2011). By 
contrast, paired box 6 (Pax6), expressed after Sox1, induces neuroectoderm to 
differentiate into radial glial and subsequently neuronal cells (Warren et al., 1999, Mo 
and Zecevic, 2008, Sansom et al., 2009).  Similarly, the transition from neurogenesis to 
gliogenesis is regulated by the sequential expression of pro-neuronal and pro-astroglial 
cytokines and morphogenic factors in addition to cell intrinsic mechanisms that act on 
multi-potent radial glial populations.  At the onset of neurogenesis, precursor cell pools 
differentiate preferentially into neuronal cells under the availability of pro-neuronal 
cytokines such as neurogenin, while gliogenic genes are repressed through methylation, 
and transcription factors inhibited through protein modification (Deverman and 
Patterson, 2009).  These inhibitory mechanisms are coupled with the reduced availability 
of pro-glial cytokines, which altogether support the differentiation of neuronal cells while 
restricting the astroglial differentiation.  As neurogenesis progresses, the accumulation 
of neuronal proteins, such as cardiotrophin-1 (CT-1), a gp130 cytokine expressed by 
newly differentiated neurons, induces astroglial differentiation through activation of the 
Stat3 (Sauvageot and Stiles, 2002, Barnabe-Heider et al., 2005).   
 
3.1.2 Stat 3 in neurodevelopmental disorders  
Maternal immune dysregulation, following prenatal infection and resultant 
expression of cytokines such as IL6 provide a unique opportunity for neuropathological 
consequences due to the disruption of the Stat3 pathway, and the developmental events 
it regulates.  Murine models of Stat3 mutations have highlighted the role of Stat3 in 
neuropathological outcomes as these models have yielded observations ranging from 
disruptions in synaptic transmission, neuronal migration, and abnormal neuronal and 
glial morphologies to embryonic lethality depending on the extent of the mutation 
(Campbell et al., 1993, Brunello et al., 2000). Particularly, disruptions in synaptic 
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transmission, potentially due to neuronal overgrowth or astroglial abnormalities have 
been thought to precipitate the behavioral pathologies in animals possessing these 
mutations.  Similar disruptions in neuronal populations have also been implicated in the 
behavioral abnormalities observed clinically in disorders such as ASD (Campbell et al., 
1993, Brunello et al., 2000).   
The ability of IL6 mediated Stat3 disruptions to alter astroglial differentiation and 
function may particularly suggest an indirect mechanism of precipitating these 
pathologies.  During development, expression and subsequent binding of gp130 
cytokines such as CT-1 to the gp130-Janus tyrosine kinase-2/Signal Transducer and 
Activator of Transcription-3 (Jak2/Stat3) receptor complex triggers a series of 
phosphorylation including the activation of Stat3, its entry into the nucleus and 
subsequent transcription of astroglial genes such as GFAP (Akira, 1997, Heinrich et al., 
1998, Deverman and Patterson, 2009).  Astrocytes are important constituents of the 
CNS providing migratory scaffolding for neurons during development and the later 
regulating synaptic transmission through the release of neuroactive compounds, 
clearance of neurotransmitters from the synaptic cleft, or direct communication with 
neurons (Brunello et al., 2000).  Disruption of astroglial function have been shown to 
have deleterious effects, and has been implicated in disorders such as epilepsy, a 
condition found to be a common comorbidity with ASD in a subset of this population 
(Dutuit et al., 2000, Brenner et al., 2001, Laurence and Fatemi, 2005, Vargas et al., 
2005, Jabs et al., 2008).  Astrocyte disruptions have also been directly implicated in the 
pathology of ASD with disruptions in several astroglial markers including GFAP elevated 
in the brains of autistic individuals, a potential fetal inflammatory response to prenatal 
infection (Fatemi et al., 2008a).  Stat3 mediated regulation of astrocyte development and 
function is therefore important in regulating CNS function. 
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3.2 Results 
3.2.1 Luteolin attenuates IL-6 mediated neuronal Jak2/Stat3 phosphorylation  
The effects of IL-6 has been shown to be a largely Stat3 dependent event.  
During CNS development, the maintenance of stem cell populations through active 
proliferation and the initiation of gliogenesis in neural stem cells have also been shown 
to be mediated by activation of Stat3.  To determine the efficacy of luteolin in attenuating 
IL-6/Stat3 mediated activation and resultant pathologies, Jak2/Stat3 phosphorylation 
was measured in murine neuroblastoma (Neuro-2a) cells.  IL-6, like other gp130 
cytokines bind to their respective gp130 receptor complex to activate Stat3 through a 
series of phosphorylation events beginning with the phosphorylation of Jak2, followed by 
the phosphorylation, dimerization and nuclear entry of Stat3.  Once in the nucleus, Stat3 
binds target DNA sequences to initiate the transcription of Stat3 dependent genes such 
as glial fibrillary acidic protein (GFAP) at the onset of gliogenesis.  To examine IL-6 
mediated activation of the Jak2/Stat3 pathway, Neuro-2a cells were treated with 50 
ng/mL of murine recombinant IL-6 (mIL-6) in a time dependent manner.  Alternatively, 
cells were also co-treated with mIL-6 and increasing concentration of luteolin (0µM - 
20µM) for 30 minutes.  Western blot analysis of cell lysates showed that IL-6 treatment 
induced a time dependent increase in Jak2 phosphorylation beginning at 30 minutes and 
continuing until 75 minutes, when the timed analysis was concluded (fig. 3.1a).  When 
cell lysates of luteolin co-treated cells were analyzed, there was significant inhibition of 
Jak2 phosphorylation observed beginning at 10µM. 
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Figure 3.1a-b 
Luteolin attenuated IL-6 mediated Jak2 phosphorylation in neuroblastoma cells. 
Densitometric analysis of the ratio of phospho Jak2 to total Jak2, and one way ANOVA 
showed mIL-6 treatment significantly induced Jak2 phosphorylation in a time dependent 
manner beginning at 30 minutes (**p<0.005) (a).  Luteolin co-treatment significantly 
inhibited the effects of IL-6, attenuating IL-6 mediated phosphorylation beginning at 
10µM (**p<0.01) (b). 
** 
** 
a 
b 
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Stat3 phosphorylation in Neuro-2a cells was analyzed next.  IL-6 treatment 
resulted in a significant increase in Stat3 phosphorylation at residue Ser727 beginning at 
30 minutes, and remaining significant until the end of treatment at 75 minutes.  Luteolin 
co-treatment significantly inhibited IL-6 mediated Stat3 phosphorylation beginning at 
10µM.   
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Figure 3.2a-b 
Luteolin attenuated IL-6 mediated Stat3 phosphorylation in neuroblastoma cells. 
Densitometric analysis of the ratio of phosphor Stat3 to total Stat3, and one way ANOVA 
showed mIL-6 treatment significantly induced Stat3 phosphorylation in a time dependent 
manner beginning at 30 minutes (**p<0.005) (a).  Luteolin co-treatment significantly 
attenuated this phosphorylation beginning at 10 µM (*p<0.01, **p<0.001) (b).  Similar 
results were obtained using antibody specifically against phospho-Star3 (Tyr705).  
 
** 
** 
** 
* 
** 
** 
b 
a 
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3.2.2 Luteolin attenuates IL-6 mediated effects in neural stem cells through 
inhibition of the Jak2/Stat3 phosphorylation  
Although neuroblastoma cells are often utilized as an in vitro model to examine 
CNS pathologies the effects of IL-6 and the therapeutic efficacy of luteolin was further 
examined in neural stem cells isolated from embryonic mouse cortices, to closer 
approximate the in vivo environment during CNS development.  Phosphorylation of Jak2 
was examined following mIL-6 treatment or luteolin and mIL-6 co-treatment.  In cultures 
treated with mIL-6 Jak2 phosphorylation was significantly increased at 15 minutes post 
treatment, reaching a maximal intensity at 45 minutes (fig. 3.3a).  When Stat3 
phosphorylation was examined, there was a similar phosphorylation pattern observed 
with a significant increase in phosphorylation in response to IL-6 treatment at residue 
Tyr705.  Phosphorylation at residue Ser727 was significant at 45 minutes (fig. 3.3c).  
Luteolin co-treatment significantly inhibited IL-6 mediated phosphorylation of Jak2 and 
Stat3 at both residues at 20µM (fig. 3.3b&d).   
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Figure 3.3a-b 
Luteolin attenuated IL-6 mediated phosphorylation of Jak2/Stat3 in neural stem cells.  
Densitometric analysis showed mIL-6 treatment significantly induced Jak2 
phosphorylation in a time dependent manner beginning at 15 minutes, remaining 
significant until 45 minutes (a).  This phosphorylation was attenuated by luteolin co-
treatment (b).  (*=p<0.01) 
a 
b 
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Figure 3.3c-d 
Densitometric analysis showed mIL-6 treatment significantly induced Stat3 
phosphorylation in a time dependent manner beginning at 15 minutes, remaining 
significant until 30 minutes (c).  This phosphorylation was attenuated by luteolin co-
treatment (d).  (*=p<0.01) 
* 
* 
* 
c 
d 
* 
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3.2.3 Luteolin attenuates IL-6 mediated activation of Protein kinase B (Akt) and 
Migtogen activated protein kinase (Erk1/Erk2) pathways in neural stem 
cells  
Although Stat3 has been shown to be a key transcription factor and regulatory 
agent during neurodevelopment, other pathways, such as protein kinase B, also known 
as Akt, and mitogen activated protein kinase or Erk1/Erk2 have been shown to play 
important roles.  These pathways have also been shown to interact and regulate the 
activity of Stat3 and are responsive to IL-6 treatment.  Erk1/Erk2 for example in addition 
to regulating neuronal differentiation has been shown to regulate Stat3 activity at Ser727, 
through phosphorylation.  Although the exact purpose of this event is not fully 
understood, it has been hypothesized that Erk1/Erk2 mediated serine phosphorylation 
regulates Stat3 homodimerization, while other groups have hypothesized a role in 
regulating transcriptional activity and DNA binding (Wen et al., 1995, Zhang et al., 1995, 
Chung et al., 1997).  The effects of luteolin on these pathways were examined as well.  
In neural stem cells cultures treated with IL-6 there were significant increases in Akt 
phosphorylation and Erk1/Erk2 phosphorylation at which was inhibited by luteolin co-
treatment.  Although it is not clear how activation of these pathways, or inhibition by 
luteolin for that matter impacts the pathological effects of mIL-6, or the ability of luteolin 
to attenuate these events, their interactions with Stat3, and role in development suggest 
that they may play some role in regulation. 
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Figure 3.4 
 
Luteolin attenuated IL-6 mediated phosphorylation of Protein kinase B (Akt) in neural 
stem cells.  Densitometric analysis showed mIL-6 treatment significantly induced Akt 
phosphorylation in a time dependent manner beginning at 15 minutes, remaining 
significant until 30 minutes (a).  This phosphorylation was attenuated by luteolin co-
treatment (b).  (*=p<0.01) 
*  
* 
a 
b 
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Figure 3.5a-b 
Luteolin attenuated IL-6 mediated phosphorylation of Mitogen activated protein kinase 
(Erk1/Erk2) in neural stem cells.  Densitometric analysis showed mIL-6 treatment 
significantly induced Stat3 phosphorylation in a time dependent manner beginning at 15 
minutes, remaining significant until 30 minutes (a).  This phosphorylation was attenuated 
by luteolin cotreatment (b).  (*=p<0.01) 
* 
* * 
a 
b 
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3.2.4 Luteolin attenuates IL-6 induced proliferation in neuroblastoma cells 
Increases in the number of neuronal cells in certain regions of the brain have 
been one pathological feature described in ASD, and may be attributed to disruptions in 
the proliferative or apoptotic mechanisms during key phases of neurodevelopment.  
Activation of the Stat3 pathway by gp130 cytokines has been shown to be a potent 
inducer of proliferation, with dysregulation of Stat3 being an important mechanism in 
certain cancers.  The potential of IL-6 to induce proliferation in neuronal cells was 
examined in Neuro-2a cells.  Undifferentiated and differentiated Neuro-2a were treated 
with murine recombinant IL-6 (mIL-6) for 24hours and proliferation measured as a 
function of fluorescent intensity of labeled nucleic acid residues.  IL-6 treatment 
significantly increased proliferation in undifferentiated Neuro-2a cells at even minimal 
concentrations of 1.625ng/mL, with proliferation peaking at 12.5ng/mL.  Although this 
proliferative effect declined with increasing concentration, 25 – 100ng/mL, it remained 
significant in comparison to control levels (fig. 3.6a).  By contrast, in differentiated N2a 
cells, the effects of IL6 on proliferation were minimal, peaking at 3.125ng/mL and 
declining significantly thereafter although remaining marginally significant (fig. 3.6b).    
 
 
 
 
 
 
 
32 
 
 
 
 
 
Figure 3.6a-b 
Luteolin attenuates IL-6 induced proliferation in neuroblastoma cells.  Measurement of 
fluorescent intensity, from labeled nucleic acid residues indicated that mIL6 treatment 
significantly increased proliferation in undifferentiated n2a cells, with fluorescent intensity 
doubling at 1.625ng/mL (p0.0002), and peaking at 12.5ng/mL (p0.0003) (a).  In 
differentiated cells, the increase in proliferation was much lower albeit significant peaking 
at 3.125ng/mL (p0.009) and drastically declining thereafter. Proliferation at 100ng/mL 
was not significant (b). (* p<0.05, **p<0.01, ***p<0.001) 
 
 
a 
b 
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3.2.5 Effects of IL-6 in neural stem cells may reflect in vivo pathological 
consequences of prenatal infection. 
The development of the CNS has been shown to be largely dependent on a 
series of tightly regulated events including periods of proliferation and targeted 
apoptosis.  Although neuroblastoma cells are often utilized as an in vitro model to 
examine CNS pathologies the proliferative capabilities of IL-6 and the therapeutic 
efficacy of luteolin was further examined in neural stem cells isolated from embryonic 
mouse cortices, to closer approximate the in vivo environment.  Interestingly, the 
proliferative effects of mIL-6 observed in undifferentiated and differentiated Neuro-2a 
cells, were not replicated in neural stem cell (NSC) cultures although significant 
proliferation was still observed (fig. 3.7a).  This difference may be attributable to the 
tumorigenic nature of Neuro-2a cells which has been shown to exhibit significant 
proliferative potential and their ability to proliferate independent of exogenous growth 
factors primarily through the autocrine expression of transforming growth factors (van 
Zoelen et al., 1984).  When cells were co-treated with luteolin there was no significant 
inhibition of proliferation observed, as levels were comparable and potentially slightly 
increased to that observed in IL-6 and even control cells (fig. 3.7b). 
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Figure 3.7a-b 
Effects of IL-6 in neural stem cells may reflect in vivo pathological consequences of 
prenatal infection.  In NSC cultures, (a) mIL6 treatment resulted in a significant increase 
in proliferation at concentrations 12.5ng/mL – 50ng/mL.  (b) Luteolin treatment did not 
significant attenuate IL6 induced proliferation in NSC.  In fact there was a trend toward 
an increase in proliferation with all concentrations except 3.125uM and 50uM, which 
showed a trend toward a decrease.  (*=p<0.05) 
 
 
 
b 
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To further investigate this observation, the effects of luteolin were compared in 
the presence and absence of IL-6 treatment.  As initially eluded to in the experiment 
represented in figure 3.8b, the effects of luteolin were influenced by the presence of IL-6.  
In the absence of IL-6, luteolin co-treatment attenuated proliferation at higher 
concentrations.  When IL-6 was present, the effects of luteolin were highly variable.  This 
effect may be attributed by the presence of growth factors such as epidermal growth 
factor (EGF), which maintains stem cells in a proliferative state, and signals through 
activation of Stat3.  Stat3 has also been shown to regulated by the interactions of 
multiple signaling pathways that converge at Stat3 such as the Erk pathway.  Although 
luteolin has been shown to modulate Erk, the combined actions of IL-6 and EGF may 
impact the therapeutic effects of luteolin on inhibiting IL-6 mediated pathologies. 
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Figure 3.8 
The ability of luteolin to attenuate IL-6 mediated pathologies modulated by the presence 
of growth factors (EGF and FGF).  The proliferative effects of IL-6 in neural stem cells 
are also affected by the presence of growth factors.   
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As the proliferative effects of IL-6 and the modulatory effects of luteolin in NSC 
cultures were somewhat unexpected, proliferation was next assessed optically, using 
fluorescent microscopy. Characteristically, neural stem cells form spherical structures in 
suspension known as neurospheres when maintained in proliferative media, 
supplemented with the appropriate growth factors, described previously in chapter 2, 
section 2.1.  The effects of IL6 and luteolin co-treatment on neurosphere morphology 
and number were examined using FITC labeling of cellular nucleic acid, to confirm 
previous results.  Interestingly there again appeared to be no significant proliferative 
effects as there was no significant difference in the total amount of neurospheres or the 
size of neurospheres under the different treatment conditions.  There was however a 
trend towards a difference in neurosphere size following mIL-6 treatment, with an 
increase in medium and small neurosphere populations and a corresponding decrease 
in the large neurosphere population.  Although not significant, these effects were 
reversed by luteolin co-treatment (fig3.9).   
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Figure 3.9 
IL-6 and Luteolin does not alter neurosphere size or number.  Neurospheres were 
classified as small (less than 100um), medium (101-200um) or large (greater than 
201um).  There were no significant changes in the total population of neurospheres 
induced by treatment.  There were however changes in neurosphere size following mIL6 
treatment, with medium sized (101 – 200um) neurosphere populations increasing.  
Similarly, luteolin co-treatment did not show significant modulation of IL6 activity 
although the increase in the number of medium neurosphere population was reversed. 
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3.2.6 Luteolin attenuates IL-6 mediated morphological changes in neural stem 
cells  
The morphological effects of IL6 and luteolin co-treatment were examined next.  
IL6 treatment induced observable changes in neurosphere morphology; specifically 
there was a shift from a stem cell phenotype to a commitment to terminal differentiation 
evidenced by increased branching and attachment to the culture surface, which was 
significantly inhibited by luteolin co-treatment (fig3.10).  This effect was not evident in all 
neurosphere clones as IL6 seemed to maintain a consistent population of neurospheres 
while simultaneously inducing differentiation in others.  To further examine this effect 
cultures were treated with IL6 in the absence of growth factors.  In these cultures, 
neurosphere morphology was maintained at levels comparable to that of control 
suggesting that IL6 can maintain neural stem cells in a self-renewal phase characterized 
by continuous proliferation or shift them toward lineage commitment and differentiation.  
These effects appear to be highly dependent on the immediate microenvironment as can 
be seen from the outcomes of this experiment and the observations of proliferation in 
differentiated and undifferentiated N2a cells (fig. 3.6).  
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Figure 3.10 
Luteolin attenuates IL-6 mediated morphological changes in neural stem cells.  IL6 
treatment (GF/IL6) resulted in increased attachment of cells to the culture surface and 
increased branching and dissociation of neurospheres.  This effect was attenuated by 
luteolin co-treatment (GF/IL6-Lt).  In the absence of growth factors, cells fail to maintain 
active proliferation, resulting in significant decreases in neurosphere numbers (Control).  
IL6 treatment, in the absence of growth factors was able to maintain neurosphere 
morphology and active proliferation (IL6), an effect also attenuated by luteolin co-
treatment.   
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3.2.7 Luteolin attenuates IL-6 mediated differentiation of GFAP positive cells  
To confirm that mIL-6 had induced differentiation and lineage commitment, cells 
were fluorescently labeled with neuronal and glial specific cellular markers.  When IL-6 
treated cultures were examined there was in fact increased differentiation and lineage 
commitment evidenced by increased expression of neuronal and glial markers Beta-
tubulin and GFAP respectively.  Surprisingly, there was no corresponding decrease in 
vimentin expression, a marker of neural stem cells, further suggesting the ability of IL6 to 
maintain some cells in an uncommitted fate (fig3.11).  When cells were co-treated with 
luteolin there was a significant decrease in GFAP expression however, this effect was 
not seen with Beta-tubulin although there was a trend toward a decrease.   
Since GFAP expression has been shown to be a Stat3 dependent event, the 
selective attenuation of GFAP expression suggests luteolin effects may be mediated 
through modulation of Stat3 signaling.  Additionally, the limited effects on neuronal 
populations further confirm, a Stat3 dependent mechanism as well as suggest that the 
effects on neuronal populations may be secondary.  This secondary effect shows an 
indirect mechanism by which the function of neuronal populations are altered by the 
actions of astroglial cell populations, as these cells have been shown to be supportive to 
neuronal cells cooperating in synaptic transmission as well as providing metabolic 
support through the supply of neuroactive molecules.  
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Figure 3.11 
Luteolin attenuates IL-6 induced GFAP expression in neural stem cells.  Following 
treatment, cells were triple labeled with anti-GFAP, anti-btub and anti-vimentin and 
lineage determined and quantified using confocal microscopy and analytical software.  
IL6 treatment (GF/IL6) resulted in a significant increase GFAP (***p<0.0002) and btub 
(***p<0.0001) expression although vimentin expression remained constant.  GFAP 
expression was attenuated by luteolin co-treatment (GF/IL6-Lt) (***p<0.0005) however 
there was no significant effect observed with btub expression although there was a trend 
toward a decrease.   
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3.2.8 IL6 and luteolin activity influenced by extrinsic conditions in the cellular 
microenvironment 
 To further examine the effects of IL-6 and luteolin on lineage specification, IL6 
and luteolin co-treatment was examined in differentiated cells already committed to a 
specific cellular lineage.  When NSC cells, three days post differentiation were treated 
with IL6, there were no significant changes observed in GFAP and Beta-tubulin 
expression although both populations showed a trend toward an increase.  Interestingly, 
nestin expression, a marker of uncommitted neural stem cells, was also increased 
suggesting an increase in this population of cells.  There were also observable changes 
in neuronal morphology, specifically increased and less ordered axonal branching.  This 
effect did not appear to be significantly attenuated by luteolin co-treatment.  
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Figure 3.12 
IL-6 and Luteolin activity dependent on extrinsic factors in the cellular microenvironment.  
Neural stem cells 3 days post differentiation did not show significant changes following 
treatment although there was a trend toward an increase in Beta-tubulin and GFAP 
expression.  This trend was not attenuated by luteolin, as co-treated cultures appeared 
to show slight increases although not significant. 
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3.3 Conclusions 
Prenatal infection and the ensuing increase in maternal cytokines, has been 
regarded as a key etiological factor in the pathogenesis of neurodevelopmental 
disorders such as ASD.  IL6, already described as a key mediator in inflammatory 
disorders, and an important immune regulator, has been cited as being critical to the 
adverse outcomes following prenatal infection, as increases in this cytokine have been 
strongly correlated to disease pathology, pathologies which have been ameliorated by 
following IL-6 inhibition.  Additionally, inhibition of this cytokine during prenatal infection 
has been shown to attenuate pathological outcomes.  In this chapter, the efficacy of 
flavonoids such as luteolin in reducing IL-6 mediated pathologies was examined in NSC, 
an in vitro model of the effects of prenatal infection on the fetal CNS.  Luteolin co-
administration was able to attenuate the pathological effects of IL6 particularly increases 
in proliferation and excess glial cell expression.  Targeted luteolin attenuation of glial cell 
commitment, a Stat3 dependent event, and its attenuation of Stat3 phosphorylation 
suggest that the neuropathologies were mediated through IL6-Stat3 activation and that 
the inhibition of this pathway may be therapeutically beneficial.    
A somewhat unexpected but noteworthy observation was the dependence of 
mIL-6 activity on cell extrinsic and intrinsic factors, as the pathologies observed in 
undifferentiated cells were significantly different than those seen in differentiated cells.  
These observations support epidemiological findings that suggest that there is an ‘ideal 
window’ where the effects of prenatal infection are more deleterious.  In the in vitro 
model utilized in this chapter, the effects of IL-6 seemed most significant in 
undifferentiated stem cells which suggest that early infections may be most detrimental 
to CNS development.  Several studies have emphasized these findings in vivo 
suggesting earlier infections provide an ideal opportunity for disruption of key processes 
such as cellular proliferation and differentiation.  These disruptions precipitate further 
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pathologies including alterations in cellular migration and synapse development which 
manifest clinically in the neurological and behavioral abnormalities observed in disorders 
such as ASD and schizophrenia which have been correlated with prenatal infection 
(Meyer et al., 2007).  Dopaminergic neurons for example have been shown to emerge 
during the early phases of neurodevelopment from precursor populations both in murine 
animals and in humans (Bayer et al., 1995, Brana et al., 1996, Marti et al., 2002).  
Prenatal infection and resultant maternal and/or fetal cytokine expression during this 
period can lead to disruptions in the proliferation, differentiation, migration of these cells 
and subsequent disruptions in dopaminergic cellular populations (Brown et al., 2004).  It 
is plausible that these neuropathologies induced by prenatal infection may account for 
the behavioral and neurological abnormalities observed in disorders such as 
schizophrenia where disruptions in the dopaminergic system have been a consistent 
finding.  These findings however do not preclude the ability of prenatal infection during 
late gestation to induce adverse pathological outcomes.  Indeed infections during this 
developmental window have been shown to induce disruptions in cellular migration, 
neuronal organization, and synaptogenesis (Buka et al., 2001, Gilmore et al., 2004).   
It is evident that infections during pregnancy have to potential to lead to adverse 
neurological outcomes in exposed offspring and the timing of infection may impact the 
nature of pathologies observed clinically.  Early infections allow for opportunities to 
disrupt proliferation, differentiation and migration of cellular populations that can lead to 
multiple morphological, structural and functional abnormalities due to the potential to 
impact multiple cellular populations.  By contrast, later infections may have more 
targeted effects, producing disruptions to the positioning and interactions of specific 
cellular populations that may be vulnerable due to migration, synapse formation (Buka et 
al., 2001, Meyer et al., 2007).  The implications of these divergent outcomes can be 
seen in the nature of the pathologies attributed to earlier infections, where 
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symptomology is often more heterogeneous as can be seen in disorder such as ASD 
and schizophrenia.  By contrast, later infections may give rise to certain cognitive deficits 
and similar neurological abnormalities.  
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CHAPTER 4 
FLAVONOIDS, A PRENATAL PROPHYLAXIS FOR ADVERSE PERINATAL 
OUTCOMES AFTER PRENATAL INFECTION 
 
4.1 Prenatal infection, Cytokines and the Placental Barrier 
The pleiotropic nature of cytokines, particularly their involvement in both 
pathological and physiological events and their ubiquitous expression throughout the 
body and at various developmental periods make them prime targets as mediators of the 
adverse outcomes resulting from prenatal infection.  Despite evidence of their function in 
this capacity however, there is still disagreement as to their role in neurodevelopmental 
and/or neuropsychiatric disorders such as ASD (Dassa et al., 1995, Chen et al., 2004).  
Adding to this disagreement has been a lack of consensus as to whether or not maternal 
cytokines, produced during prenatal infection, can traverse the placental barrier and 
disrupt fetal development.  Research focusing on the placental migration of cytokines, 
following prenatal infection has yielded contradictory results with some studies reporting 
a positive results while others have reported no migration (Bell et al., 2004, Aaltonen et 
al., 2005, Ashdown et al., 2006).  These contradictions may be attributed to variations in 
experimental design as comparative studies have shown that the ability of maternal 
cytokines to traverse the placental barrier may be highly dependent on the time of 
immune challenge.  IL-6 for example has been shown to traverse the rat placenta during 
mid-gestation, approximately embryonic days 11–13, while this observation is not seen 
during embryonic days 17–19 (Bell et al., 2004, Dahlgren et al., 2006). 
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It is worthwhile to note, that even with no observable cytokine migration during 
late gestation, prenatal infection during this period has still been shown to increase 
cytokine levels in the fetal CNS, and precipitate adverse neurological outcomes. 
Additionally, murine models of prenatal infection utilizing LPS, which does not traverse 
the placental barrier, have induced both maternal and fetal inflammatory responses 
following prenatal administration (Bell et al., 2004, Elovitz et al., 2011).  These findings 
suggest that instances of prenatal infection not only activate the maternal immune 
system, but can propagate a cascade of inflammatory responses inducing inflammation 
in the placenta as well as the fetal CNS. This can in turn lead to adverse changes in 
placental function and the development and function of the fetal CNS. 
 
4.1.1 Current animal models of adverse perinatal outcomes following prenatal 
infection  
Although the mechanism by which maternal cytokines disrupt fetal CNS 
development is not fully understood, findings from animal models have highlighted their 
role in the pathological changes that may precipitate later neuroanatomical, 
immunological and behavioral abnormalities in prenatally exposed offspring.  In murine 
models of prenatal influenza exposure, neuropathologies including changes in cell 
density, cell atrophy and neurochemical abnormalities such as disruptions in serotonin 
levels were observed.  These pathologies mirror clinical findings in disorders such as 
schizophrenia and ASD, and may explain the alterations in the levels of 
neurotransmitters such as serotonin and its metabolites observed in these disorders 
(Fatemi et al., 2002, Meyer et al., 2008, Winter et al., 2008).  Behavioral correlates 
among prenatally exposed murine offspring have also been observed.  Particularly 
deficits in prepulse inhibition in adult offspring following prenatal exposure to bacterial 
endotoxin LPS or synthetic viral analog polyinosinic:polycytidylic acid (poly(I:C)) have 
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been observed, a pathology representative of deficits in sensorimotor gating, an inability 
to filter out extraneous information, and a well-known pathological feature in disorders 
such as ASD and schizophrenia (Fortier et al., 2007). 
 In addition to neurodevelopmental abnormalities, these models have also shown 
instances of pregnancy disorders including preeclampsia and spontaneous recurrent 
miscarriages that seem to result from disruptions in maternal immunity (Makhseed et al., 
2000, Laresgoiti-Servitje et al., 2010, Tosun et al., 2010, Holder et al., 2011, Jin et al., 
2011).  These disorders have described observations of aberrant T cell differentiation 
with uncharacteristic increases in cytotoxic T cell populations, an IL-6 influenced event, 
and reductions in immune suppressant T cell populations (Kimura and Kishimoto, 2010, 
Fujimoto et al., 2011).  This scenario contrast observations in normal pregnancies where 
increases in the number of immunosuppressive T-regs preceding and after implantation 
of the fetus, prevent the proliferation and activation of cytotoxic Th17 cells ensuring the 
ability to maintain a viable pregnancy (Aluvihare et al., 2004, Heikkinen et al., 2004, 
McCracken et al., 2004, Somerset et al., 2004, Hunt et al., 2005, Zenclussen et al., 
2006, Kallikourdis et al., 2007, Kallikourdis and Betz, 2007, Kahn and Baltimore, 2010, 
Dimova et al., 2011).  IL6 has therefore been shown to be a recurrent pathological 
feature and potential site of intervention in disorders precipitated by prenatal infection. 
 
4.1.3 Luteolin as a therapeutic intervention – potential mechanism 
As the inhibition of IL-6 and its mediated activation of Stat3 are known to reduce 
pathological outcomes following prenatal infection, prenatal flavonoid treatment may 
prove to be of therapeutic value for both maternal and fetal pathologies.  Several studies 
have shown that flavonoids are potent anti-inflammatory agents that act through 
modulation of tyrosine kinase activity to inhibit cytokine production, and the expression 
of other pro-inflammatory mediators.  This has been confirmed in studies involving 
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stimulation of immune cells with flavonoids such as luteolin resulting in a reduction in the 
expression of cytokines such as IL6 and Tumor necrosis factor-alpha (TNF-α), with 
inhibition of Stat3, nuclear factor kappa light chain enhancer of activated B cells (NF-κB) 
and Protein Kinase B (Akt) being implicated as potential mechanisms (Hirano et al., 
2006, Jang et al., 2008, Zhu et al., 2011).   
 
4.2 Results   
4.2.1 Luteolin attenuates maternal immune response following prenatal infection 
 Activation of the maternal immune system following prenatal infection, 
particularly the release of maternal cytokines has been cited as the major contributor to 
adverse perinatal outcomes.  Particularly, disruptions in cytokine expression and T-cell 
differentiation have been cited as key mediators in adverse perinatal events through 
their disruption of placental function.  The spleen is an important immune organ and 
source of pro-inflammatory cytokines.  During prenatal infection, the spleen has been 
shown to be an important mediator of the maternal inflammatory response and cytokine 
expression (Athanassakis and Iconomidou, 1996).  Here, splenocytes isolated from 
female C57BL/6 mice were challenged with lipopolysaccharide (LPS) or concavalin A 
(conA) and co-treated with luteolin to examine attenuation of inflammatory responses 
and splenic cytokine expression.  LPS is a bacterial endotoxin utilized in animal models 
to elicit immune reactions including pro-inflammatory cytokine production, while. conA is 
often utilized as a T-cell mitogen.  When LPS challenged splenocyte cultures were co-
treated with luteolin, there was a significant inhibition of IL-6 and TNF-α expression.  
Similarly, in cultures challenged with conA, luteolin co-treatment also significantly 
inhibited IL-6 and TNF- α expression. 
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Figure 4.1a-b 
Luteolin attenuates pro-inflammatory cytokine expression from LPS or conA challenged 
splenocytes.  Elisa cytokine analysis showed luteolin co-treatment significantly inhibits 
LPS mediated IL6 (a) and TNF-α (b) expression from splenocyte cultures in a 
concentration dependent manner (***p<0.001).  These results represent five 
independent experiments. 
 
a 
b 
 55 
 
 
 
 
 
Figure 4.1c-d 
Elisa cytokine analysis showed luteolin co-treatment significantly inhibits LPS mediated 
IL6 (c) and TNF-α (d) expression from splenocyte cultures in a concentration dependent 
manner (***p<0.001).  These results represent five independent experiments. 
a 
b 
*** 
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 To further confirm the efficacy of flavonoids such as luteolin in attenuating 
maternal immune activation during prenatal infection, cytokine production was further 
examined in the spleens of recently delivered prenatally infected mice.  As IL-6 mediated 
activation of Stat3 have been shown to play a critical role in immune regulation, 
particularly in the propagation of inflammatory responses, including the differentiation of 
cytotoxic or pro-inflammatory T-cell populations, and pro-inflammatory cytokine 
expression following infection, the role of Stat3 in mediating this inflammation, and the 
ability of luteolin to attenuate Stat3 activation was also examined.  Pregnant mice were 
treated with 5 µg/mL mIL-6, 50ug/kg LPS, or co-treated with these compounds in the 
presence of 10mg/kg luteolin at embryonic day 12 (E12).  Mice injected prenatally with 
LPS and IL6 showed significant increases in TNF-α and interleukin1- β (IL1-β) 
expression which was attenuated by luteolin co-treatment.   
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Figure 4.2a-b 
Luteolin attenuates maternal immune responses following prenatal infection.  Luteolin 
co-treatment significantly inhibited cytokine production in spleens from mice prenatally 
injected with LPS or IL-6.  Luteolin alone also significantly reduced cytokine expression 
below that of control levels (***p<0.001).   
 Stat3 has also been shown to play a major role in the progression of 
b 
a 
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inflammatory processes following infection.  Additionally, IL-6 mediated activation of 
Stat3 has been implicated as key in the differentiation of cytotoxic T-cell populations 
from naïve T-cells.  Stat3 activity was analyzed and the effect of luteolin co-treatment 
was assessed in spleens isolated from prenatally treated mice.  In mice treated 
prenatally with LPS, there was a significant increase in Stat3 phosphorylation confirming, 
its involvement in potentiating inflammatory responses.  When luteolin was co-
administered with LPS, Stat3 phosphorylation was significantly reduced, to levels 
comparable to that of control animals.   
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Figure 4.3 
Luteolin attenuates Stat3 phosphorylation in maternal spleens following prenatally 
infection.  Luteolin co-treatment significantly inhibited Stat3 phosphorylation in spleens 
from mice prenatally injected with LPS or IL6 (**p<0.05).   
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4.2.2 Luteolin attenuates adverse fetal outcomes following prenatal infection  
 Several adverse perinatal events including premature delivery, in utero growth 
restriction, and often more serious outcomes such as neurological disorders, recurrent 
miscarriages and preeclampsia have been attributed to prenatal infection.  Attenuation of 
the maternal immune response to infection may serve as a therapeutic alternative not 
only for developmental outcomes but also for adverse pregnancy outcomes.  In mice 
exposed prenatally to LPS or IL-6 at E12, there was a significant decrease in the birth 
weight of offspring suggestive of in utero growth restriction.  This effect was attenuated 
by luteolin co-treatment.  An unexpected result of luteolin treatment was an apparent 
increase in birth weight.  There were no visible abnormalities observed after treatments. 
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Table 4.1 
Luteolin attenuates adverse fetal outcomes following prenatal infection. 
Treatment Ctl/PBS LPS IL6 LPS/Lt IL6/Lt 
Average litter weight 1.33±0.10 1.27±0.13* 1.25±0.09* 1.35±0.13* 1.36±0.13* 
 
 
 
Figure 4.4 
Luteolin attenuates adverse fetal outcomes following prenatal infection.  Offspring 
exposed prenatally to IL6 showed an average decrease in birth weight when compared 
to their non-exposed counterparts (*p<0.05).  This was attenuated by luteolin, although 
there was an increase in birth weight associated with luteolin treatment (*p<0.05).  There 
were no observable physical abnormalities observed. 
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4.2.3 Diosmin reduced pro-inflammatory cytokine production and Jak2/Stat3 
phosphorylation in the brain tissues of IL-6 newborn mice 
To further expand on the efficacy of flavonoid treatment during instances of 
prenatal infection, an in vivo model of dietary intervention was utilized.  For the following 
experiments, pregnant mice were treated with 5ug/mL mIL-6 in the presence or absence 
of diosmin (10 mg/kg/day diosmin) administered orally in their chow from E12 until birth.  
As a positive control, a subgroup of mice were co-treated with IL-6 and Stat3 inhibitor 
S31-201 (4ug/mL) at embryonic day 12 (E12).  Cytokine production and Jak2/Stat3 
phosphorylation was examined in the brain homogenates of new born mice.  In mice 
prenatally exposed to IL-6, there was a significant increase in pro-inflammatory 
cytokines TNF-α and IL-1β levels compared to controls.  These increases were 
significantly reduced by almost 50% in the presence of S31-201 or diosmin.  Western 
blot analysis of brain homogenates show that both S31-201 and diosmin significantly 
reduce IL-6 induced Jak2 and Stat3 phosphorylation.  
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Figure 4.5 
Diosmin reduced pro-inflammatory cytokine production in the brain homogenates of 
prenatally exposed newborn mice.  Pro-inflammatory cytokine analysis by ELISA was 
conducted on these newborn mouse brain homogenates.  Analysis of results revealed a 
significant reduction of TNF-α and IL-1β cytokines in brain homogenates from IL-6/S31-
201 and IL-6/Diosmin/newborn mice when compared to IL-6 only (MIA model) newborn 
mice (**P < 0.01). 
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Figure 4.6 
 
Diosmin reduced Jak2/Stat3 phosphorylation in the brain homogenates of prenatally 
exposed newborn mice.  Brain homogenates were prepared from newborn mice from 
mothers injected with IL-6, IL-6/S31-201, IL-6/diosmin or PBS (control).  Treatment of 
S31-201 or diosmin significantly inhibited IL-6-induced Jak2/Stat3 phosphorylation in 
brain tissues from newborn mice.  Densitometry analysis shows the ratio of phospho-
Jak2/Stat3 to total Jak2/Stat3 as indicate below the figures.  One-way ANOVA showed 
that both significantly inhibit Jak2/Stat3 signaling (P <0.005).   
 
 
 
 
 
 
 
 
 65 
 
4.2.4 Prenatal diosmin co-treatment reduces abnormal behaviors in offspring 
following prenatal infection through inhibition of Stat3 pathway 
Abnormal social behaviors, and in some instances anxiety are prominent 
features in disorders such as ASD and schizophrenia.  To further examine the efficacy of 
flavonoid dietary intervention in attenuating the pathological effects of prenatal infection, 
the behavior of adult offspring exposed prenatally to IL-6 and flavonoid intervention was 
examined.  The open field test was used to assess general locomotor activity and 
anxiety while the social interaction test was used to assess social behaviors.  Pregnant 
mice were treated as described in the previous section and their adult offspring 
examined for behavioral outcomes.  In mice exposed prenatally to IL-6, there were 
significant behavioral disruptions observed.  In the open field test, these mice spent less 
time in the inner section compared to control, S31-201 or diosmin treated mice.  
Offspring of mice co-treated with either S31-201 or diosmin showed behaviors 
comparable to that of control mice.  The open field test measures anxiety as a function 
of entries the test animal makes into an arbitrarily defined ‘center’.  Since this measure is 
highly dependent on the total distance travelled within the apparatus, changes in 
locomotor activity in one group could significantly skew the outcome measures.  To 
account for this, ANOVA on distance traveled in the inner section was performed and did 
not indicate a main effect.  Analyses of distance traveled in the outer section did not 
reveal a significant difference or a statistical trend towards a significant difference among 
groups.  There was not a significant difference between PBS-treated mice and S31-
treated control (non-IL-6 injected) mice.  
In the social interaction test, the adult offspring of control mice showed a strong 
preference for the social chamber, almost double that of the adult offspring of IL-6 
treated mice confirming impairments in social behaviors in mice exposed prenatally to 
IL-6.  This social impairment was significantly reduced by maternal co- treatment with 
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S31-201 or diosmin as these mice showed a preference for the social chamber 
comparable to that of control adult offspring.  To quantify social interaction, exploration 
demonstrated as sniffing time was analyzed via ANOVA.  There was a main effect of 
group; the S31-201 or diosmin mice exhibited an increase in sniffing compared to IL-
6/MIA mice.  There were no observations of social grooming, chasing, dominant mounts, 
pinning, boxing, or biting.  There were no significant differences in total move time and 
total distance traveled.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
 
 
Fig. 4.7 
Maternally blocking Stat3 activity reduces abnormal behaviors in prenatally exposed 
animals.  Offspring of mice (n = 8, 4 female/4 male) intraperitoneally (i.p.) treated with IL-
6 (5 µg/mouse) in the absence or presence of STAT3 inhibitor (S31-201; 4 µg/mouse; 
i.p.) (Siddiquee et al., 2007) or with diosmin [oral administration; (10 mg/kg/day)].  (a) In 
the open-field test, offspring of mice treated with either S31-201 or diosmin enter the 
center more often than IL-6 (**P < 0.01) and are nearly similar to control mice.  (b) In the 
social interaction test, as previously reported, the social chamber was defined as 
(percentage of time in social chamber) – (percentage of time in opposite chamber).  
Most notably, control mice reveal a strong preference for the social chamber.  
Interestingly, the social impairment of offspring is significantly improved by maternal 
administration of STAT3 inhibitor, S31-201 or diosmin (**P < 0.005).     
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4.2.5 Diosmin reduces pro-inflammatory cytokines and Stat3 phosphorylation in 
prenatally exposed animals 
After behavioral testing, adult offspring were sacrificed to confirm that inhibition of 
Stat3 phosphorylation by diosmin attenuates IL-6/Stat3 induced behavioral 
abnormalities.  At sacrifice, brain homogenates were prepared from control mice and 
mice exposed prenatally to IL-6, IL-6/S31-201, and IL-6/Diosmin.  Pro-inflammatory 
cytokine ELISA showed significant increases in TNF-α and IL-1β levels in the 
homogenates of IL-6 adult offspring.  Maternal co-treatment with S31-201 or diosmin 
significantly reduced TNF-α and IL-1β cytokine levels, with diosmin showing slightly 
more significant reductions as shown in Fig. 4.8.  
Western blot analysis of phospho- and total Stat3 showed that prenatal IL-6 
treatment increased Stat3 phosphorylation in the brain homogenates of adult offspring 
while co-treatment with either S31-201 or diosmin lead to a significant reduction of 
STAT3 phosphorylation.  This data suggest that activation of the Stat3 pathway following 
prenatal infection is a plays a major role in the resultant pathologies including behavioral 
deficits.  Inhibition of Stat3 activation, by diosmin reduces these behavioral deficits and 
may be a key therapeutic intervention strategy. 
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Fig. 4.8 
Diosmin reduces pro-inflammatory cytokine expression in the brain homogenates of 
prenatally exposed animals.  Pro-inflammatory cytokine analysis by ELISA revealed a 
significant reduction of TNFα and IL-1β cytokines in brain homogenates from IL-6/31-
201 and IL-6/Diosmin adult offspring when compared to offspring prenatally exposed to 
IL-6 only.(**P < 0.05).   
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Fig. 4.9 
Diosmin attenuates Stat3 phosphorylation in the brain homogenates of prenatally 
exposed animals.  Western blot analysis showed a significant reduction of STAT3 
phosphorylation in brain homogenates from IL-6/S31-201 and IL-6/Diosmin/adult 
offspring when compared to offspring of IL-6 offspring.  These reductions were further 
showed by densitometric analysis (**P < 0.005).  
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4.3 Discussion 
 Epidemiological data, clinical findings from pregnancy disorders and 
observations from murine models of prenatal infection have supported a role for 
activation of the maternal immune system, and subsequent maternal cytokine 
expression as a key component of their pathological mechanism (Hwang and Chen, 
Brown et al., 2000, Brown and Susser, 2002, Li et al., 2009, Atladottir et al., 2010).  
Furthermore, IL-6 has been shown to be an important mediator of these pathological 
events through its dysregulation of the Stat3 pathway.  This chapter shows how 
flavonoids luteolin and diosmin not only attenuate IL-6 mediated Stat3 activity but more 
importantly the adverse maternal and fetal outcomes stemming from prenatal infection.   
To confirm the ability of luteolin to attenuate maternal immune responses during 
prenatal infection, cytokine production from the spleen was examined following an 
immunological challenge.  The spleen is an important mediator during immune activation 
and a reservoir of pro-inflammatory cytokines.  In splenocytes challenged with LPS or 
conA luteolin co-treatment significantly inhibited IL-6 and TNF-α expression.  
Immunological disruption including increased IL-6 expression has been shown to be a 
consistent feature in adverse perinatal outcomes precipitated by prenatal bacterial or 
viral infections or instances of chronic immunological dysregulation.  Increased plasma 
levels of IL-6 for example has been observed in FIRS precipitated by bacterial infections 
as well as in preeclampsia, thought to be connected to immunological disruptions 
(Gomez et al., 1998, Chaiworapongsa et al., 2002, Tosun et al., 2010, Zhou et al., 
2011).  The ability of luteolin to inhibit inflammatory response to both LPS and conA 
suggest it may be a key therapeutic alternative in a wide range of pregnancy disorders 
as these two mitogens elicit immune reactions through very different mechanisms. 
These findings were also confirmed by in vivo analysis.  When spleens isolated 
from recently delivered mice challenged with LPS or IL-6 were analyzed, TNF-α and IL-
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1β, were reduced by luteolin in co-treatment.  TNF-α and IL-1β have both been shown to 
indirectly induce IL-6 expression and Stat3 activity (Mori et al., 2011).  As increased 
Stat3 activity is a known consequence of IL-6 expression, this was also examined.  Stat3 
phosphorylation was significantly reduction by luteolin co-treatment in prenatally 
challenged animals.  The attenuation of maternal immunological disruptions and 
cytokine expression by luteolin also reduced fetal pathological outcomes, particularly 
growth restrictions, as mice exposed prenatally to LPS or IL-6 had significantly lower 
birth weights than control offspring, a pathology not seen in the offspring of mice that 
received luteolin co-treatment. 
It is clear that maternal immunological disruptions following prenatal infection 
play an important role in adverse perinatal outcomes, however fetal immunological 
responses have also been observed to play an equally important role in pathologies, 
particularly the neurological abnormalities observed in prenatally exposed offspring 
(Dammann and Leviton, 2000, Chaiworapongsa et al., 2002).  To examine the ability of 
flavonoids to attenuate fetal immune responses, fetal cytokine expression and Stat3 
activity were examined in newborn and adult offspring, while abnormal behaviors were 
analyzed in the adult offspring of prenatally exposed animals.  A more chronic 
administration route of flavonoid treatment was also examined.  Diosmin dietary 
intervention was utilized to examine prenatal supplementation of flavonoids and their 
effects on fetal outcomes.  Similar to maternal outcomes, there was an increase in 
inflammatory cytokines and Stat3 phosphorylation in the brains of prenatally exposed 
animals which was attenuated by diosmin co-treatment.  Additionally, behavioral deficits 
observed in these animals were also attenuated following diosmin co-treatment.  It is 
therefore evident that flavonoid co-treatment is a beneficial therapeutic intervention in 
prenatal infection, as it can reduce the neuropathological and abnormal behavioral 
outcomes seen in prenatally exposed offspring. 
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CHAPTER 5 
CONCLUSION 
 
Clinical observations in disorders such as preeclampsia, schizophrenia and ASD 
have highlighted the role of maternal immune activation and subsequent IL-6 
expression, often a consequence of prenatal infection, in the pathological features 
observed in these disorders.  Similarly, murine models replicating these disorders have 
identified this immune reaction and IL-6 expression as a central component of the 
pathological mechanism.  Studies have also shown that IL-6 may be a measurable 
indicator of pathology and target of therapeutic intervention as inhibition of IL6 has been 
shown to reduce associated disease pathology (Smith et al., 2007, Zhou et al., 2011).  In 
disorders such as preeclampsia for example, elevations in IL-6 have been implicated as 
an observable and measurable mediator of hypertension through its regulation of 
vasoconstrictive proteins and its inhibition has been shown to reduce this pathology 
(Zhou et al., 2011).  Similarly, in models of prenatal infection meant to recapitulate 
neurodevelopmental disorders such as ASD, IL-6 has been shown to induce not only the 
neuropathologies such as abnormal cellular morphology, but also abnormal behaviors 
such as impaired social interactions, outcomes all attenuated by inhibition of IL-6 (Smith 
et al., 2007).   
This study further explores how prenatal infection can lead to adverse perinatal 
outcomes, particularly changes in neuroanatomy that seem to precipitate the abnormal 
behavioral outcomes observed in prenatally exposed offspring and clinically in disorders 
such as ASD.  More specifically, it focuses on role of IL-6 mediated activation of the 
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Stat3 pathway in these pathologies and how attenuation of this pathway, by flavonoids 
can reduce the pathological outcomes associated with prenatal infection.  Chapter three 
explores this relationship by utilizing an in vitro model of pathological IL-6 expression to 
examine the neuropathologies that may occur following prenatal infection and 
subsequent exposure to IL-6.  Treatment of neural stem cells with IL-6 revealed 
significant pathologies including increases in proliferation, and aberrant patterns of 
differentiation.  Most notably, and possibly most relevant to clinical observations in 
disorders such as ASD were findings of increased astroglial differentiation following IL-6 
treatment, an effect inhibited by luteolin co-treatment.  Astrocyte pathologies have been 
implicated in neurological disorders such as epilepsy due largely to their role in 
regulating synaptic transmission, and their supportive role in maintaining optimal 
neuronal function and integrity in the CNS (Brunello et al., 2000, Dutuit et al., 2000, 
Brenner et al., 2001).  These types of pathologies may be particularly relevant in 
disorder such as ASD as increased expression of astroglial markers such as GFAP and 
aquaporin 4 have been observed in post mortem autistic brain samples (Fatemi et al., 
2004, Laurence and Fatemi, 2005, Fatemi et al., 2008a).  When NSC cultures were co-
treated with IL-6 and luteolin, astroglial differentiation, a Stat3 mediated event was 
significantly reduced.  An examination of Stat3 phosphorylation showed that this was 
also significantly reduced following luteolin co-treatment suggesting prenatal luteolin 
treatment has the potential to attenuate IL-6/Stat3 mediated pathologies. 
To expand on these findings, luteolin’s effects were investigated in vivo.  The 
effects of chronic prenatal administration were also examined using diosmin.  The 
experiments outlined in chapter four looked at the ability of luteolin and diosmin to inhibit 
activation of the maternal immune system as well as adverse fetal outcomes such as low 
birth weight, indicative of in utero growth restriction and abnormal behaviors.  To look at 
maternal immune reactions, luteolin activity was examined in splenocyte cultures as well 
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as the spleens of recently delivered prenatally exposed animals.  Luteolin treatment was 
able to attenuate inflammatory response following prenatal infection, an event mediated 
by attenuation of Stat3 phosphorylation, which was also inhibited by luteolin co-
treatment.  Specifically, luteolin inhibited expression of IL-6 and TNF-α in splenocytes 
challenged with LPS or conA, confirming the ability of luteolin to attenuate maternal 
immune responses independent of the pathogenic stimuli.  In spleen tissue, luteolin 
inhibited TNF-α and IL-1β expression in the spleens of mice challenged with IL-6 or LPS.  
Like IL-6, these cytokines have been shown to be elevated following prenatal infection 
and during other instances of immune dysregulation and can indirectly induce IL-6 
expression and resultant activation of Stat3 (Mori et al., 2011).   
The inhibition of maternal immune activation following prenatal infection by 
luteolin suggests fetal pathologies resulting from prenatal infection can also be 
attenuated by prenatal flavonoid treatment.  To confirm this, several fetal outcomes were 
examined, including birth weight, as decreased birth weight is a known consequence of 
prenatal infection.  As expected, prenatal infection not only activated the maternal 
immune system but also led to decreased birth weight in exposed offspring a feature 
often correlated to subsequent neurological deficits.  These effects were significantly 
inhibited by luteolin co-treatment.  The neurological consequences of prenatal infection 
were examined next.  Although maternal cytokine expression has been noted as central 
to the pathologies attributed to prenatal infection, fetal immune activation has also been 
observed and are considered a key mediator of the neuropathologies and resultant 
neurological deficits observed in exposed offspring.  Chronic flavonoid administration as 
a potential prophylactic intervention was examined next using diosmin dietary 
supplementation.  Examination of the brain homogenates of newborn mice exposed 
prenatally to IL-6 showed significant increases in TNF-α and IL-1β expression as well as 
increased Stat3 phosphorylation.  In the offspring of animals maintained on a diosmin 
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enriched diet from the time of prenatal challenge until birth, these pathologies were 
inhibited.  To confirm the role of Stat3 activity in the neurological deficits following prental 
infection, behavioral outcomes were examined in prenatally exposed adult offspring.  
The efficacy of flavonoids and inhibition of IL-6/Stat3 activity in reducing these abnormal 
behavioral outcomes were also examined.  In mice prenatally exposed to IL-6, there 
were significant behavioral abnormalities observed including deficits in social interaction, 
a prominent feature in ASD and schizophrenia.  In animals co-treated with diosmin, this 
deficit was significantly attenuated.  More importantly, analysis of brain homogenates 
following behavioral assessment showed an attenuation of pro-inflammatory cytokine 
production and Stat3 phosphorylation. 
Currently there is no cure for ASD and therapeutic interventions focus primarily 
on the management of symptoms, utilizing behavioral therapy to control the abnormal 
behaviors and pharmacological intervention to manage comorbid conditions.  The role of 
prenatal infection in precipitating adverse pregnancy and fetal outcomes has not only 
provided a potential mechanism but a focus for therapeutic intervention as targeted 
inhibition of IL6 and Stat3 activation has been shown to attenuate, and in many cases 
completely ameliorate pathological outcomes.  In addition to neurological disorders 
attributed to prenatal infection, disorders of pregnancy such as preeclampsia and 
recurrent spontaneous abortions share a similar pathology to those precipitated by 
prenatal infection due to the involvement of maternal immune dysregulation.  This 
overlap in pathological features suggests that modulation of the maternal immune 
system may also be beneficial in these disorders and may be a potential therapeutic 
alternative.  While some of these disorders such as recurrent miscarriages seem to be 
characterized by a persistent dysregulation of the maternal immune system and may 
require more aggressive and chronic treatments, others such as preeclampsia often 
appear more transient with a sudden onset of pathological symptoms and may benefit 
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from short term interventions.  The results of this study show the potential for both 
chronic and one time flavonoid intervention to yield significant therapeutic effects.  
Additionally, the relative safety of many of these flavonoid compounds make their 
application during pregnancy for chronic or transient treatment feasible as compounds 
such as diosmin have already been shown to be safe when administered during 
pregnancy (Buckshee et al., 1997).  Although there is room for more research in this 
area, the potential application of flavonoid compounds, particularly diosmin and luteolin, 
is evident in light of their therapeutic efficacy in attenuating both maternal and fetal 
adverse outcomes during periods of maternal immune activation, or dysregulation. 
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